<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infection</z:e> with HIV is independently associated with an increased risk for clinical <z:hpo ids='HP_0001635'>heart failure</z:hpo>, <z:hpo ids='HP_0001638'>cardiomyopathies</z:hpo> and <z:hpo ids='HP_0004416'>premature atherosclerosis</z:hpo>, including <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> in both the pre-HAART and HAART eras </plain></SENT>
<SENT sid="1" pm="."><plain>HAART is also associated with clinical cardiovascular concerns </plain></SENT>
<SENT sid="2" pm="."><plain>In HIV-infected individuals, HAART may cause adverse <z:chebi fb="23" ids="18059">lipid</z:chebi> profiles and increased risk for cardiovascular events </plain></SENT>
<SENT sid="3" pm="."><plain>Its effects on the developing heart remain unclear </plain></SENT>
<SENT sid="4" pm="."><plain>Although in utero HAART exposure may improve cardiac function in the first 2 years of life, it may also inhibit myocardial growth </plain></SENT>
<SENT sid="5" pm="."><plain>Additional potentially damaging cardiovascular effects of HAART are present, and continuing cardiovascular risk evaluations, screening and follow-up of treated patients is necessary </plain></SENT>
<SENT sid="6" pm="."><plain>Here, we review available research in this field and highlight the importance of understanding known complications and their mechanisms </plain></SENT>
</text></document>